Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Reports Q2 Revenue Gains

NEW YORK, Aug. 5 (GenomeWeb News) - Caliper Life Sciences today reported a 222 percent gain in second-quarter revenues, driven by sales from Zymark, which the firm acquired in July 2003.

 

Caliper had revenues of $18.9 million in the quarter, up from $5.9 million in the second quarter of 2003.

 

The Hopkinton, Mass.-based firm posted a net loss of $9.5 million, or $.33 per share, compared to a net loss of $9.5 million, or $.38 per share, in the comparable period last year. This year's second-quarter results include a $2.4 million restructuring charge related to future lease costs of facilities no longer occupied following consolidation of its Mountain View, Calif., operations. The results also included $180,000 in severance charges and related benefits incurred in connection with the elimination of 14 positions.

 

Caliper finished the quarter with $52.9 million in cash, equivalents and short-term marketable securities.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.